Candel Therapeutics Reveals Early Survival Data From Lung Cancer Trial

Candel Therapeutics Inc CADL announced updated activity data from its ongoing, open-label, phase 2 trial of CAN-2409 plus valacyclovir in combination with continued immune checkpoint inhibitor (ICI) treatment in patients with non-resectable, stage III/IV non-small cell lung cancer (NSCLC), who have an inadequate response to front line anti-PD(L)1 therapy. 

These patients historically have had an expected median overall survival of 10-13 months. 

The aim of the CAN-2409 immunotherapy antitumor strategy is to raise the tail on the survival curve by increasing the number of long survivors beyond 10-13 months.

Also Read: Candel Therapeutics Says One Dose Of CAN-3110 Shows Encouraging Responses In A Type Of Brain Cancer.

Of the 40 evaluable patients, 15 have lived ≥ 12 months; of these, 10 patients have lived > 18 months, of whom 70% (7/10) were alive as of the last follow-up. 

All four patients (100%) with OS > 24 months were alive at the last follow-up, with the longest reaching 31.7 months.

An additional 18 out of the 40 evaluable patients are also alive but have not yet reached 12 months of follow-up.

Candel continued to observe a favorable safety/tolerability profile after CAN-2409 treatment.

Candel expects to share topline overall survival data for Cohort 2 in the second quarter of 2024, assuming mature data then.

Price Action: CADL shares are down 18.24% at $0.92 on the last check Tuesday.